.png)
Forty million cancer diagnostic scans happen each year using isotopes produced by reactors—most of them overseas and built in the 1960s. Tech Brew recently examined what happens when that aging supply chain breaks down and how new technology could provide a more reliable alternative.
Most molybdenum-99 currently comes from foreign reactors that are increasingly prone to outages. When these facilities go down for maintenance or experience unexpected problems, patients face postponed procedures and treatment delays.
We're building infrastructure to change that reality. Our Chrysalis facility in Wisconsin will be among the world's largest medical isotope production sites, with capacity to produce up to 20 million doses of Mo-99 annually. By using fusion-based neutron sources rather than depending on foreign reactors, we're creating a domestic supply chain designed for reliability. Once operational, the facility will offer hospitals and pharmaceutical partners a dependable U.S.-based source.
The need is only growing. As the population ages and radiopharmaceutical applications expand into cardiology and Alzheimer's treatment, stable isotope supply becomes essential infrastructure. Other companies are also advancing production through particle accelerators and complementary technologies.
Read the full article at Tech Brew to understand how multiple approaches are converging to strengthen medical isotope availability for patients who depend on these treatments.
